BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
70.72
-3.21 (-4.34%)
Feb 19, 2026, 4:00 PM EST - Market closed
BridgeBio Pharma Employees
As of December 31, 2024, BridgeBio Pharma had 730 total employees, including 725 full-time and 5 part-time employees. The number of employees increased by 174 or 31.29% compared to the previous year.
Employees
730
Change (1Y)
174
Growth (1Y)
31.29%
Revenue / Employee
$484,630
Profits / Employee
-$1,091,942
Market Cap
13.63B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 730 | 174 | 31.29% | 725 | 5 |
| Dec 31, 2023 | 556 | 160 | 40.40% | 550 | 6 |
| Dec 31, 2022 | 396 | -182 | -31.49% | 392 | 4 |
| Dec 31, 2021 | 578 | 182 | 45.96% | 576 | 2 |
| Dec 31, 2020 | 396 | 148 | 59.68% | 385 | 11 |
| Sep 30, 2020 | 369 | 159 | 75.71% | 369 | 0 |
| Jun 30, 2020 | 328 | 143 | 77.30% | 328 | 0 |
| Mar 31, 2020 | 296 | 144 | 94.74% | 296 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Moderna | 5,800 |
| BioMarin Pharmaceutical | 3,040 |
| Genmab | 3,029 |
| Jazz Pharmaceuticals | 2,800 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| Ionis Pharmaceuticals | 1,069 |
| Madrigal Pharmaceuticals | 528 |
BBIO News
- 2 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 days ago - BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET - GlobeNewsWire
- 7 days ago - Allspring Growth Fund Q4 2025 Fund Performers And Detractors - Seeking Alpha
- 7 days ago - BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript - Seeking Alpha
- 8 days ago - BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - GlobeNewsWire
- 11 days ago - BridgeBio: Initiating At A Neutral Rating, Stock Priced At Perfection - Seeking Alpha
- 23 days ago - CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 - GlobeNewsWire